2012

Novartis Pharmaceuticals Achieves Dismissal of Bisphosphonate Claims

Novartis Pharmaceuticals received a voluntary dismissal of claims from plaintiffs for their bisphosphonate drug in the midst of a trial. Novartis manufactures and sells Zometa, a drug indicated to strengthen bone in cancer patients whose disease has metastasized to bone.

Faegre Baker Daniels served as lead trial counsel in the case. This was one of hundreds of similar cases against Novartis ongoing across the country. Brown v. Novartis Pharmaceuticals Corp., No. 7:08-cv-00130-FL (E.D. NC 2012)

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.